Bausch Health jumps as Delaware court guards diarrhea drug's patent

Bausch Health Companies

17/05/2023 19:15

** U.S.-listed shares of Bausch Health Co Inc  BHC.N  up 26%
at $7.51 - set to see best day in 7 years if gains hold
    ** Delaware district court denies revision to court's final
judgment preventing a generic version of Xifaxan, co's
antibiotic drug for traveler's diarrhea 
   ** The ruling prevents Norwich Pharma from getting its
generic version of the diarrhea drug approved before Oct. 2,
2029 which is the patent expiry date for Xifaxan
    ** Shares of Bausch had crashed to a 25-year low in July,
after Delaware court judge Richard Andrews had said parts of
BHC's patents related to Xifaxan were not valid
    ** Xifaxan is a top seller and is owned by BHC's
gastroenterology unit Salix Pharmaceuticals 
    ** Stock up 18.3% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))